Today's Rundown After exiting troubled Merrimack, former CEO becomes new chief at Yumanity From biotech CEO to ‘expert patient:’ HPV awareness advocate Michael Becker dies FDA accepts BLA filing for Sanofi's rival to J&J's Darzalex Revolution Medicines snags $100M to attack RAS-mutated cancers Osivax raises €8M for universal flu vaccine clinical trials Eisai launches first startup incubator under its genomics center for dementia 23andMe therapeutics leader leaves for board roles at up-and-coming biotechs Featured Story | | | Wednesday, July 10, 2019 Last month, he was the chief executive of struggling Merrimack; today, he’s the new CEO at Fierce 15 winner and early-stage biotech Yumanity as Sanofi-Genzyme veteran Richard Peters looks to move on. |
|
|
| This week's sponsor is Medrio. | | | [Webinar] Accelerating Site and Patient Enrollment for Phase 1 Trials
Tuesday, July 23 | 2pm ET / 11am PT
This Fierce webinar will feature clinical trial site leaders and R&D executives, who will pass along the latest strategies for boosting site and patient enrollment in phase 1 trials. They will discuss best practices for communicating with both investigators and patients. Register Now! |
Top Stories Wednesday, July 10, 2019 Michael Becker, the former biotech CEO who spent his life working on new drugs and then turned to raising awareness of the cancer that would eventually kill him, has died of head and neck cancer that had spread to his lungs. Wednesday, July 10, 2019 The FDA has accepted Sanofi’s filing for approval of its Darzalex rival in relapsed/refractory multiple myeloma. Sanofi will learn whether the FDA will approve anti-CD38 antibody isatuximab by the end of April 2020. Wednesday, July 10, 2019 Revolution Medicines raised $100 million in series C financing to advance a stable of drugs aiming at what it calls “frontier targets” in cancer. Wednesday, July 10, 2019 Osivax has raised €8 million to take a universal flu vaccine candidate through early-phase development. The series A round comes as Osivax nears the delivery of phase 1 data on a candidate that achieved widespread protection in mice and ferrets. Tuesday, July 9, 2019 Eisai opened its first startup incubator as part of its new Cambridge, Massachusetts-based center focused on exploring the genetic links to dementia and potential immunotherapies. Wednesday, July 10, 2019 23andMe’s chief scientific officer and former therapeutics foreman Richard Scheller has left the sequencing company and landed on the boards of at least two biotechs—namely, two of the biggest money raisers of the year so far. | This week's sponsor is ExL Events. | | | |
Resources Sponsored by: Almac Group Innovative Just in Time Manufacturing solution enables sponsors full late stage customisation of clinical trial materials Sponsored by: PwC How are employer activism strategies beginning to replace the cost-sharing of the past, and improve the health of the workforce? Sponsored by: United Cargo and SAVSU Technologies The combination of SAVSU technology with United Airlines’ global network has made it easier than ever to bring cell and gene therapies to destinations beyond major markets. Sponsored by: XiltriX North America Find out in this article how your pharmaceutical organization can leverage IoT technologies and informatics integration to innovate and improve overall operational efficiencies. Sponsored by: Patheon, by Thermo Fisher Scientific When a biologics company prepares to launch a new product, it must forecast the manufacturing capacity it will need. Learn more here. Sponsored by: Veradigm Patient demand for more information on their care is driving new e-prescribing regulations, and technology is evolving to help providers meet them. This report provides an overview of key areas where such regulation has emerged, and what it could mean for providers and healthcare IT companies. Sponsored by: Patheon, by Thermo Fisher Scientific Anticipate challenges in formulation early. Sponsored by: Titian Software This Essential Guide to Managing Laboratory Samples is a three-part piece exploring common problems experienced in the management of samples and how, for any scale of operation, significant efficiency and accuracy benefits can be gained using dedicated sample management software. Sponsored by: Veradigm Patients living with diabetes deserve better – Real-World Evidence for effecting/realizing change in the management of type 2 diabetes and cardiovascular/renal comorbidities. Sponsored by: Catalent Download the case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study. Sponsored by: Catalent Watch a short video on demand led supply model. It is designed to meet the needs of patients, clinical sites, clinical team and sponsors and results in shorter lead time, less waste, less stock out risk and no booklet labels. Sponsored by: Catalent Download the eBook to explore a proactive approach for clinical supply management. Latin America Healthcare Compliance Certificate Program September 23-26, 2019 4th FierceBiotech Drug Development Forum October 28-29, 2019 | Boston, MA Drug Development Boot Camp® 2019 November 20-21, 2019 | Boston, MA | Register NOW and start Pre-Boot Camp Preparation! | 